메뉴 건너뛰기




Volumn 392, Issue 5, 2007, Pages 511-523

Current concepts and perspectives of immunosuppression in organ transplantation

Author keywords

Calcineurin inhibitor sparing; De novo recurrence of cancer; Drug related side effects; Impaired renal function; Individually tailored immunosuppression; mTOR inhibitor; Steroid avoidance; True prope tolerance

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; 4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; AEB 071; ALEMTUZUMAB; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; FINGOLIMOD; FRESENIUS; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LEFLUNOMIDE; LYMPHOCYTE ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLACEBO; PREDNISONE; PROTEIN KINASE C INHIBITOR; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

EID: 34547843499     PISSN: 14352443     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00423-007-0188-z     Document Type: Review
Times cited : (32)

References (102)
  • 2
    • 0036192366 scopus 로고    scopus 로고
    • CHIC 304 International liver study group improved treatment response with basiliximab immunoprophylaxis after liver transplantation: Results from a double-blind randomized placebo-controlled trial
    • Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, Ortmann E, Chodoff l, Hall M, Korn A, Nashan B (2002) CHIC 304 International liver study group improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transplant 8:132-142
    • (2002) Liver Transplant , vol.8 , pp. 132-142
    • Neuhaus, P.1    Clavien, P.A.2    Kittur, D.3    Salizzoni, M.4    Rimola, A.5    Abeywickrama, K.6    Ortmann, E.7    Chodoff, L.8    Hall, M.9    Korn, A.10    Nashan, B.11
  • 5
    • 31044451821 scopus 로고    scopus 로고
    • Lymphocyte alloresponses of Campath-1H-treated kidney transplant patients
    • 1
    • Bloom DD, Hu H, Fechner JH, Knechtle SJ (2006) Lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. Transplantation 81(1):81-87
    • (2006) Transplantation , vol.81 , pp. 81-87
    • Bloom, D.D.1    Hu, H.2    Fechner, J.H.3    Knechtle, S.J.4
  • 6
    • 33746921599 scopus 로고    scopus 로고
    • The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation
    • 9
    • Magliocca JF, Knechtle SJ (2006) The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int 19(9):705-714
    • (2006) Transpl Int , vol.19 , pp. 705-714
    • Magliocca, J.F.1    Knechtle, S.J.2
  • 7
    • 33750945467 scopus 로고    scopus 로고
    • How does alemtuzumab affect long-term graft and patient outcomes after deceased-donor kidney transplantation?
    • 2
    • Knechtle SJ (2005) How does alemtuzumab affect long-term graft and patient outcomes after deceased-donor kidney transplantation? Nat Clin Pract Nephrol Dez 1(2):74-75
    • (2005) Nat Clin Pract Nephrol Dez , vol.1 , pp. 74-75
    • Knechtle, S.J.1
  • 9
    • 33744906053 scopus 로고    scopus 로고
    • Alemtuzumab (Campath-1H): A systematic review in organ transplantation
    • 10
    • Morris PJ, Russell NK (2006) Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation 81(10):1361-1367
    • (2006) Transplantation , vol.81 , pp. 1361-1367
    • Morris, P.J.1    Russell, N.K.2
  • 10
    • 0032490341 scopus 로고    scopus 로고
    • Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients
    • 9117
    • Calne R, Friend P, Moffatt S, Bradley A, Hale G, Firth J, Bradley J, Smith K, Waldmann H (1998) Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 351(9117):1701-1702
    • (1998) Lancet , vol.351 , pp. 1701-1702
    • Calne, R.1    Friend, P.2    Moffatt, S.3    Bradley, A.4    Hale, G.5    Firth, J.6    Bradley, J.7    Smith, K.8    Waldmann, H.9
  • 13
    • 1342304173 scopus 로고    scopus 로고
    • Lymphomas after solid organ transplantation: A collaborative transplant study report
    • Opelz G, Döhler B (2003) Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 4:222-230
    • (2003) Am J Transplant , vol.4 , pp. 222-230
    • Opelz, G.1    Döhler, B.2
  • 17
    • 18544363571 scopus 로고    scopus 로고
    • Clinical experience with everolimus (Certican): A summary
    • Ponticelli C (2005) Clinical experience with everolimus (Certican): a summary. Transplantation 79:93-94
    • (2005) Transplantation , vol.79 , pp. 93-94
    • Ponticelli, C.1
  • 18
    • 0037623421 scopus 로고    scopus 로고
    • Ten years of sirolimus therapy in orthotopic liver transplant recipients
    • Neff GW, Moltalbano M, Tzakis AG (2003) Ten years of sirolimus therapy in orthotopic liver transplant recipients. Transplant Proc 35:209-216
    • (2003) Transplant Proc , vol.35 , pp. 209-216
    • Neff, G.W.1    Moltalbano, M.2    Tzakis, A.G.3
  • 19
    • 33750578442 scopus 로고    scopus 로고
    • Sirolimus as the main immunosuppressant in the early postoperative period following liver transplantation: A report of six cases and review of the literature
    • Vivarelli M, Vetrone G, Zanello M, Barba GL, Cucchetti A, Lauro A, Grazi GL, Pinna AD (2006) Sirolimus as the main immunosuppressant in the early postoperative period following liver transplantation: a report of six cases and review of the literature. Transpl Int 19:1022-1225
    • (2006) Transpl Int , vol.19 , pp. 1022-1225
    • Vivarelli, M.1    Vetrone, G.2    Zanello, M.3    Barba, G.L.4    Cucchetti, A.5    Lauro, A.6    Grazi, G.L.7    Pinna, A.D.8
  • 22
    • 0033743247 scopus 로고    scopus 로고
    • Experience with the use of sirolimus in liver transplantation-use in patients for whom calcineurin inhibitors are contraindicated
    • 6
    • Chang GJ, Mahanty HD, Quan D, Freise CE, Ascher NL, Roberts JP, Stock PG, Hirose R (2000) Experience with the use of sirolimus in liver transplantation-use in patients for whom calcineurin inhibitors are contraindicated. Liver Transplant 6(6):734-740
    • (2000) Liver Transplant , vol.6 , pp. 734-740
    • Chang, G.J.1    Mahanty, H.D.2    Quan, D.3    Freise, C.E.4    Ascher, N.L.5    Roberts, J.P.6    Stock, P.G.7    Hirose, R.8
  • 26
    • 33644678828 scopus 로고    scopus 로고
    • Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation
    • Hamdy AF, El-Agroudy AE, Bakr MA, Mostafa A, El-Baz M, El-Shahawy el-M, Ghoneim MA (2005) Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. Am J Transplant 5:2531-2538
    • (2005) Am J Transplant , vol.5 , pp. 2531-2538
    • Hamdy, A.F.1    El-Agroudy, A.E.2    Bakr, M.A.3    Mostafa, A.4    El-Baz, M.5    El-M, E.6    Ghoneim, M.A.7
  • 30
    • 0033565555 scopus 로고    scopus 로고
    • Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment: A preliminary report
    • 1
    • Papatheodoridis GV, O'Beirne J, Mistry P, Davidson B, Rolles K, Burroughs AK (1999) Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment: a preliminary report. Transplantation 68(1):155-157
    • (1999) Transplantation , vol.68 , pp. 155-157
    • Papatheodoridis, G.V.1    O'Beirne, J.2    Mistry, P.3    Davidson, B.4    Rolles, K.5    Burroughs, A.K.6
  • 33
    • 25144502966 scopus 로고    scopus 로고
    • Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: A multicenter randomized clinical trial
    • Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Cantarovich M, Peltekian KM, Lilly LB, Scudamore CH, Bain VG, Wall WJ, Roy A, Balshaw RF, Barkun JS (2005) Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transplant 11:1064-1072
    • (2005) Liver Transplant , vol.11 , pp. 1064-1072
    • Yoshida, E.M.1    Marotta, P.J.2    Greig, P.D.3    Kneteman, N.M.4    Marleau, D.5    Cantarovich, M.6    Peltekian, K.M.7    Lilly, L.B.8    Scudamore, C.H.9    Bain, V.G.10    Wall, W.J.11    Roy, A.12    Balshaw, R.F.13    Barkun, J.S.14
  • 35
    • 4444253301 scopus 로고    scopus 로고
    • The impact of thymoglobulin on renal function and calcineurin inhibitor initiation in recipients of orthotopic liver transplant: A retrospective analysis of 298 consecutive patients
    • Tchervenkov JI, Tzimas GN, Cantarovich M, Barkun JS, Metrakos P (2004) The impact of thymoglobulin on renal function and calcineurin inhibitor initiation in recipients of orthotopic liver transplant: a retrospective analysis of 298 consecutive patients. Transplant Proc 36:1747-1752
    • (2004) Transplant Proc , vol.36 , pp. 1747-1752
    • Tchervenkov, J.I.1    Tzimas, G.N.2    Cantarovich, M.3    Barkun, J.S.4    Metrakos, P.5
  • 37
    • 0036440599 scopus 로고    scopus 로고
    • Non-melanoma skin cancer risk in the Queensland renal transplant population
    • 5
    • Ramsay HM, Fryer AA, Hawley CM, Smith AG, Harden PN (2002) Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol 147(5):950-956
    • (2002) Br J Dermatol , vol.147 , pp. 950-956
    • Ramsay, H.M.1    Fryer, A.A.2    Hawley, C.M.3    Smith, A.G.4    Harden, P.N.5
  • 38
    • 33644924057 scopus 로고    scopus 로고
    • A population-based study of skin cancer incidence and prevalence in renal transplant recipients
    • 3
    • Moloney FJ, Comber H, O'Lorcain P, O'Kelly P, Conlon PJ, Murphy GM (2006) A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 154(3):498-504
    • (2006) Br J Dermatol , vol.154 , pp. 498-504
    • Moloney, F.J.1    Comber, H.2    O'Lorcain, P.3    O'Kelly, P.4    Conlon, P.J.5    Murphy, G.M.6
  • 39
    • 0037374350 scopus 로고    scopus 로고
    • Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: A prospective study in Queensland, Australia
    • 3
    • Carroll RP, Ramsay HM, Fryer AA, Hawley CM, Nicol DL, Harden PN (2003) Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: a prospective study in Queensland, Australia. Am J Kidney Dis 41(3):676-683
    • (2003) Am J Kidney Dis , vol.41 , pp. 676-683
    • Carroll, R.P.1    Ramsay, H.M.2    Fryer, A.A.3    Hawley, C.M.4    Nicol, D.L.5    Harden, P.N.6
  • 41
    • 0035968626 scopus 로고    scopus 로고
    • Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: Nested cohort crossover study
    • Marcil I, Stern RS (2001) Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 358:1042-1045
    • (2001) Lancet , vol.358 , pp. 1042-1045
    • Marcil, I.1    Stern, R.S.2
  • 43
    • 0033608372 scopus 로고    scopus 로고
    • Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma
    • Freise CE, Ferrell L, Liu T, Ascher NL, Roberts JP (1999) Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma. Transplantation 67:510-513
    • (1999) Transplantation , vol.67 , pp. 510-513
    • Freise, C.E.1    Ferrell, L.2    Liu, T.3    Ascher, N.L.4    Roberts, J.P.5
  • 45
    • 0032574187 scopus 로고    scopus 로고
    • Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: Randomised comparison of two cyclosporin regimens
    • 9103
    • Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, Soulillou JP (1998) Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 351(9103):623-628
    • (1998) Lancet , vol.351 , pp. 623-628
    • Dantal, J.1    Hourmant, M.2    Cantarovich, D.3    Giral, M.4    Blancho, G.5    Dreno, B.6    Soulillou, J.P.7
  • 50
    • 33749127216 scopus 로고    scopus 로고
    • Development of de novo cancer in p53 knock-out mice is dependent on the type of long-term immunosuppression used
    • 6
    • Koehl GE, Gaumann A, Zuelke C, Hoehn A, Hofstaedter F, Schlitt HJ, Geissler EK (2006) Development of de novo cancer in p53 knock-out mice is dependent on the type of long-term immunosuppression used.Transplantation 82(6):781-786
    • (2006) Transplantation , vol.82 , pp. 781-786
    • Koehl, G.E.1    Gaumann, A.2    Zuelke, C.3    Hoehn, A.4    Hofstaedter, F.5    Schlitt, H.J.6    Geissler, E.K.7
  • 52
    • 0029929560 scopus 로고    scopus 로고
    • Risk of HBV reinfection after liver transplantation in HBsAg-positive cirrhosis. Primary hepatocellular carcinoma is not a predictor for HBV recurrence. the European Cooperative Study Group on Liver Cancer and Transplantation
    • Mazzaferro V, Regalia E, Montalto F, Pulvirenti A, Brunetto F, Lerut J, Gennari L (1996) Risk of HBV reinfection after liver transplantation in HBsAg-positive cirrhosis. Primary hepatocellular carcinoma is not a predictor for HBV recurrence. The European Cooperative Study Group on Liver Cancer and Transplantation. Liver 16:117-122
    • (1996) Liver , vol.16 , pp. 117-122
    • Mazzaferro, V.1    Regalia, E.2    Montalto, F.3    Pulvirenti, A.4    Brunetto, F.5    Lerut, J.6    Gennari, L.7
  • 53
    • 0037469018 scopus 로고    scopus 로고
    • Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy
    • Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE Jr (2003) Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 75:1396-1399
    • (2003) Transplantation , vol.75 , pp. 1396-1399
    • Eason, J.D.1    Nair, S.2    Cohen, A.J.3    Blazek, J.L.4    Loss Jr., G.E.5
  • 54
    • 33750080739 scopus 로고    scopus 로고
    • Corticosteroid-free strategies in liver transplantation
    • O'Grady JG (2006) Corticosteroid-free strategies in liver transplantation. Drugs 66:1853-1862
    • (2006) Drugs , vol.66 , pp. 1853-1862
    • O'Grady, J.G.1
  • 58
    • 0034887724 scopus 로고    scopus 로고
    • Steroid-free liver transplantation using rabbit antithymocyte globulin induction: Results of a prospective randomized trial
    • 8
    • Eason JD, Loss GE, Blazek J, Nair S, Mason AL (2001) Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial. Liver Transplant 7(8):693-697
    • (2001) Liver Transplant , vol.7 , pp. 693-697
    • Eason, J.D.1    Loss, G.E.2    Blazek, J.3    Nair, S.4    Mason, A.L.5
  • 63
    • 33644613271 scopus 로고    scopus 로고
    • Induction with rabbit antithymocyte globulin versus induction with corticosteroids in liver transplantation: Impact on recurrent hepatitis C virus infection
    • Nair S, Loss GE, Cohen AJ, Eason JD (2006) Induction with rabbit antithymocyte globulin versus induction with corticosteroids in liver transplantation: impact on recurrent hepatitis C virus infection. Transplantation 81:620-622
    • (2006) Transplantation , vol.81 , pp. 620-622
    • Nair, S.1    Loss, G.E.2    Cohen, A.J.3    Eason, J.D.4
  • 64
    • 9244243058 scopus 로고    scopus 로고
    • Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine
    • 10
    • Filipponi F, Callea F, Salizzoni M, Grazi GL, Fassati LR, Rossi M, Risaliti A, Burra P, Agnes S, De Carlis L, Valente U, Ferrara R, Pisati R (2004) Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 78(10):1488-1495
    • (2004) Transplantation , vol.78 , pp. 1488-1495
    • Filipponi, F.1    Callea, F.2    Salizzoni, M.3    Grazi, G.L.4    Fassati, L.R.5    Rossi, M.6    Risaliti, A.7    Burra, P.8    Agnes, S.9    De Carlis, L.10    Valente, U.11    Ferrara, R.12    Pisati, R.13
  • 65
    • 33644889956 scopus 로고    scopus 로고
    • Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression
    • Berenguer M, Aguilera V, Prieto M, San Juan F, Rayon JM, Benlloch S, Berenguer J (2006) Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 44:717-722
    • (2006) J Hepatol , vol.44 , pp. 717-722
    • Berenguer, M.1    Aguilera, V.2    Prieto, M.3    San Juan, F.4    Rayon, J.M.5    Benlloch, S.6    Berenguer, J.7
  • 67
    • 20444474570 scopus 로고    scopus 로고
    • The hepatoadrenal syndrome: A common yet unrecognized clinical condition
    • Hepatic Cortisol Research and Adrenal Pathophysiology Study Group
    • Marik PE, Gayowski T, Starzl TE, Hepatic Cortisol Research and Adrenal Pathophysiology Study Group (2005) The hepatoadrenal syndrome: a common yet unrecognized clinical condition. Crit Care Med 33:1254-1259
    • (2005) Crit Care Med , vol.33 , pp. 1254-1259
    • Marik, P.E.1    Gayowski, T.2    Starzl, T.E.3
  • 68
    • 1442338509 scopus 로고    scopus 로고
    • Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era
    • Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B (2004) Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4:378-383
    • (2004) Am J Transplant , vol.4 , pp. 378-383
    • Meier-Kriesche, H.U.1    Schold, J.D.2    Srinivas, T.R.3    Kaplan, B.4
  • 70
    • 0142166695 scopus 로고    scopus 로고
    • Individuality: The barrier to optimal immunosuppression
    • Kahan BD (2003) Individuality: the barrier to optimal immunosuppression. Nat Rev Immunol 3:831-838
    • (2003) Nat Rev Immunol , vol.3 , pp. 831-838
    • Kahan, B.D.1
  • 71
    • 0031586439 scopus 로고    scopus 로고
    • Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group
    • Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP (1997) Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 350:1193-1198
    • (1997) Lancet , vol.350 , pp. 1193-1198
    • Nashan, B.1    Moore, R.2    Amlot, P.3    Schmidt, A.G.4    Abeywickrama, K.5    Soulillou, J.P.6
  • 72
    • 0033556545 scopus 로고    scopus 로고
    • Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group
    • Nashan B, Light S, Hardie IR, Lin A, Johnson JR (1999) Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 67:110-115
    • (1999) Transplantation , vol.67 , pp. 110-115
    • Nashan, B.1    Light, S.2    Hardie, I.R.3    Lin, A.4    Johnson, J.R.5
  • 73
    • 0742322211 scopus 로고    scopus 로고
    • Interleukin 2 receptor antagonists for renal transplant recipients: A meta-analysis of randomized trials
    • Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC (2004) Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 77:166-176
    • (2004) Transplantation , vol.77 , pp. 166-176
    • Webster, A.C.1    Playford, E.G.2    Higgins, G.3    Chapman, J.R.4    Craig, J.C.5
  • 76
    • 0033774719 scopus 로고    scopus 로고
    • A meta-analysis of immunosuppression withdrawal trials in renal transplantation
    • Kasiske BL, Chakkera HA, Louis TA, Ma JZ (2000) A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 11:1910-1917
    • (2000) J Am Soc Nephrol , vol.11 , pp. 1910-1917
    • Kasiske, B.L.1    Chakkera, H.A.2    Louis, T.A.3    Ma, J.Z.4
  • 77
    • 9244234438 scopus 로고    scopus 로고
    • Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: A meta-analysis of randomized, controlled trials
    • Spanish Group for Evidence-Based Medicine in Renal Transplantation
    • Pascual J, Quereda C, Zamora J, Hernandez D, Spanish Group for Evidence-Based Medicine in Renal Transplantation (2004) Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. Transplantation 78:1548-1556
    • (2004) Transplantation , vol.78 , pp. 1548-1556
    • Pascual, J.1    Quereda, C.2    Zamora, J.3    Hernandez, D.4
  • 78
    • 16244380792 scopus 로고    scopus 로고
    • Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients
    • Collaborative Transplant Study
    • Opelz G, Dohler B, Laux G, Collaborative Transplant Study (2005) Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant 5:720-728
    • (2005) Am J Transplant , vol.5 , pp. 720-728
    • Opelz, G.1    Dohler, B.2    Laux, G.3
  • 82
    • 0036235312 scopus 로고    scopus 로고
    • Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: A randomized, prospective, multicenter study
    • Smak Gregoor PJ, de Sevaux RG, Ligtenberg G, Hoitsma AJ, Hene RJ, Weimar W, Hilbrands LB, van Gelder T (2002) Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 13:1365-1373
    • (2002) J Am Soc Nephrol , vol.13 , pp. 1365-1373
    • Smak Gregoor, P.J.1    De Sevaux, R.G.2    Ligtenberg, G.3    Hoitsma, A.J.4    Hene, R.J.5    Weimar, W.6    Hilbrands, L.B.7    Van Gelder, T.8
  • 89
    • 0035884710 scopus 로고    scopus 로고
    • Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure
    • Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J (2001) Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72:777-786
    • (2001) Transplantation , vol.72 , pp. 777-786
    • Johnson, R.W.1    Kreis, H.2    Oberbauer, R.3    Brattstrom, C.4    Claesson, K.5    Eris, J.6
  • 90
    • 9244246780 scopus 로고    scopus 로고
    • Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients
    • RAD B201 Study Group
    • Vitko S, Margreiter R, Weimar W, Dantal J, Viljoen HG, Li Y, Jappe A, Cretin N, RAD B201 Study Group (2004) Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 78:1532-1540
    • (2004) Transplantation , vol.78 , pp. 1532-1540
    • Vitko, S.1    Margreiter, R.2    Weimar, W.3    Dantal, J.4    Viljoen, H.G.5    Li, Y.6    Jappe, A.7    Cretin, N.8
  • 91
    • 3943072739 scopus 로고    scopus 로고
    • Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multicenter, open-label study
    • 156 Study Group
    • Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T, 156 Study Group (2004) Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 78:1332-1340
    • (2004) Transplantation , vol.78 , pp. 1332-1340
    • Nashan, B.1    Curtis, J.2    Ponticelli, C.3    Mourad, G.4    Jaffe, J.5    Haas, T.6
  • 95
    • 33746547309 scopus 로고    scopus 로고
    • Immunosuppression: Today, tomorrow and withdrawal
    • Hirose R, Vincenti F (2006) Immunosuppression: today, tomorrow and withdrawal. Semin Liver Dis 26:201-210
    • (2006) Semin Liver Dis , vol.26 , pp. 201-210
    • Hirose, R.1    Vincenti, F.2
  • 98
    • 34547851879 scopus 로고    scopus 로고
    • Experimental models and clinical relevance of spontaneous liver transplant acceptance: Facts and mechanisms
    • (in press)
    • Benseler V, McCaughan G, Schlitt HJ, Bishop GA, Bowen DG, Bertolino P (2007) Experimental models and clinical relevance of spontaneous liver transplant acceptance: facts and mechanisms. Semin Liver Dis (in press)
    • (2007) Semin Liver Dis
    • Benseler, V.1    McCaughan, G.2    Schlitt, H.J.3    Bishop, G.A.4    Bowen, D.G.5    Bertolino, P.6
  • 99
    • 33745064578 scopus 로고    scopus 로고
    • Is clinical tolerance realistic in the next decade?
    • 7
    • Ashton-Chess J, Brouard S, Soulillou JP (2006) Is clinical tolerance realistic in the next decade? Transpl Int 19(7):539-548
    • (2006) Transpl Int , vol.19 , pp. 539-548
    • Ashton-Chess, J.1    Brouard, S.2    Soulillou, J.P.3
  • 101
    • 1842525018 scopus 로고    scopus 로고
    • Metastable tolerance in nonhuman primates and humans
    • 6
    • Knechtle SJ, Burlingham WJ (2004) Metastable tolerance in nonhuman primates and humans. Transplantation 77(6):936-939
    • (2004) Transplantation , vol.77 , pp. 936-939
    • Knechtle, S.J.1    Burlingham, W.J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.